In a typical comparative clinical trial the randomization scheme is fixed at the beginning of the study, and maintained throughout the course of the trial. A number of researchers have championed a randomized trial design referred to as 'outcome-adaptive randomization.' In this type of trial, the likelihood of a patient being enrolled to a particular arm of the study increases or decreases as preliminary information becomes available suggesting that treatment may be superior or inferior. While the design merits of outcome-adaptive trials have been debated, little attention has been paid to significant ethical concerns that arise in the conduct of such studies. These include loss of equipoise, lack of processes for adequate informed consent, and inequalities inherent in the research design which could lead to perceptions of injustice that may have negative implications for patients and the research enterprise. This article examines the ethical difficulties inherent in outcome-adaptive trials.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/bioe.12084 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Author Correction: Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial.
Nat Med
November 2024
Department of Medical Epidemiology and Biostatistics, Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden.
Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial.
Nat Med
November 2024
Department of Medical Epidemiology and Biostatistics, Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden.
ProBio is the first outcome-adaptive platform trial in prostate cancer utilizing a Bayesian framework to evaluate efficacy within predefined biomarker signatures across systemic treatments. Prospective circulating tumor DNA and germline DNA analysis was performed in patients with metastatic castration-resistant prostate cancer before randomization to androgen receptor pathway inhibitors (ARPIs), taxanes or a physician's choice control arm. The primary endpoint was the time to no longer clinically benefitting (NLCB).
View Article and Find Full Text PDFA generalized outcome-adaptive sequential multiple assignment randomized trial design.
Biometrics
July 2024
Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA 15261, United States.
A dynamic treatment regime (DTR) is a mathematical representation of a multistage decision process. When applied to sequential treatment selection in medical settings, DTRs are useful for identifying optimal therapies for chronic diseases such as AIDs, mental illnesses, substance abuse, and many cancers. Sequential multiple assignment randomized trials (SMARTs) provide a useful framework for constructing DTRs and providing unbiased between-DTR comparisons.
View Article and Find Full Text PDFRationale and Design of the Randomized Bayesian Multicenter COME-TAVI Trial in Patients With a New Onset Left Bundle Branch Block.
CJC Open
August 2023
Department of Cardiology, Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada.
Patients with new-onset left bundle branch block (LBBB) after transcatheter aortic valve implantation (TAVI) are at risk of developing delayed high-degree atrioventricular block. Management of new-onset LBBB post-TAVI remains controversial. In the mparison of a Clinical onitoring Strategy Versus lectrophysiology-Guided Algorithmic Approach in Patients With a New LBBB After (COME-TAVI) trial, consenting patients with new-onset LBBB that persists on day 2 after TAVI, meeting exclusion/inclusion criteria, are randomized to an electrophysiological study (EPS)-guided approach or 30-day electrocardiographic monitoring.
View Article and Find Full Text PDFAdaptive designs for best treatment identification with top-two Thompson sampling and acceleration.
Pharm Stat
November 2023
GBDS, Bristol Myers Squibb, Berkeley Heights, New Jersey, USA.
We consider outcome adaptive phase II or phase II/III trials to identify the best treatment for further development. Different from many other multi-arm multi-stage designs, we borrow approaches for the best arm identification in multi-armed bandit (MAB) approaches developed for machine learning and adapt them for clinical trial purposes. The best arm identification in MAB focuses on the error rate of identification at the end of the trial, but we are also interested in the cumulative benefit of trial patients, for example, the frequency of patients treated with the best treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!